A single-arm, open-label, phase 0 clinical trial evaluated the intratumoral injection of c-Met-CAR-T cells modified by mRNA electroporation in six patients with metastatic breast cancer, four of whom had triple-negative breast cancer and two of whom had hormone receptor-positive cancer (NCT01837602). Here, MET is linked to triple-negative breast carcinoma.